Navigation Links
Waters Corporation Announces U.S. Drug Enforcement Administration Acquires Waters ACQUITY UPLC System to Train Forensic Chemists in Drug Screening and Profiling
Date:4/29/2009

MILFORD, Mass., April 29 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) announced today that the United States Drug Enforcement Administration (U.S. DEA) purchased a Waters(R) ACQUITY(R) UltraPerformance Liquid Chromatograph for the purpose of training new forensic chemists at the Special Testing and Research Laboratory in Dulles, Va.

Forensic laboratories are an important resource in assisting local, state and federal law enforcement agencies in monitoring and combating illicit drug abuse and trafficking, including the diversion of legally-manufactured pharmaceuticals into illegal markets. For example, data collected by the DEA from forensic laboratories about the regional use of prescription pain medicines like oxycodone and hydrocodone for non-medical purposes informs drug policy and drug enforcement initiatives and helps solve crimes. Each year, several million seized drug items are analyzed by the nation's network of government and private forensic laboratories.

Since 2004, the DEA has applied Waters ACQUITY UltraPerformance LC(R) (UPLC(R)) technology for drug profiling and has investigated this technology for drug screening analyses.

For drug profiling applications, where experts analyze trace impurities such as precursor chemicals in synthetic drugs or the constituents of natural products such as those derived from opium, a combination of UPLC and mass spectrometry (UPLC/MS/MS) has been shown to offer 2X better resolving power than HPLC and greater specificity and sensitivity than HPLC paired with photodiode array detection. These trace impurities can be important in matching a seized drug to a particular individual and potentially linking it to other cases where a similar impurity profile has been generated.

The DEA's most recent acquisition of an ACQUITY UPLC System complements its growing number of Waters ACQUITY UPLC and UPLC/MS/MS analytical systems deployed at DEA laboratories around the country.

For more information on Waters products for UPLC, visit www.waters.com/uplc.

About Waters Corporation (www.waters.com)

For 50 years, Waters Corporation (NYSE: WAT) creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, ACQUITY, UPLC, UltraPerformance LC, and ACQUITY UPLC are trademarks of Waters Corporation.


'/>"/>
SOURCE Waters Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. elephantjournal.com: Is Fluoridating Waters Giving Kids Cavities?
2. Video: Waters Highlights Impact of ACQUITY UPLC with Peer-to-Peer Scientist Testimonials
3. InVitria Headlines Sponsorship of WilBio's Waterside Conference
4. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
5. Red Cross Readies Shelters As Flood Waters Threaten to Top Levees
6. American Lung Association of Upper Midwest Offers Tips on Dealing With Floodwaters
7. AWWA partners with WaterSmart Innovations conference
8. Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work
9. Next Generation Waters Successfully Reaches Over 300 Stores!
10. Leading Spring Water Brands From Nestle Waters Team Up With the American Heart Association START! Initiative
11. Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: